Oncogenic osteomalacia

Common Name(s)

Oncogenic osteomalacia

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Oncogenic osteomalacia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Oncogenic osteomalacia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Oncogenic osteomalacia" returned 34 free, full-text research articles on human participants. First 3 results:

Localization of Oncogenic Osteomalacia by Systemic Venous Sampling of Fibroblast Growth Factor 23.
 

Author(s): Ji Yeon Lee, Hye Sun Park, Seunghee Han, Jiyu Kelly Lim, Namki Hong, Sung Il Park, Yumie Rhee

Journal: Yonsei Med. J.. 2017 Sep;58(5):981-987.

 

Tumor-induced osteomalacia (TIO) is characterized by hypophosphatemia caused by a phosphaturic mesenchymal tumor. While surgical resection of the tumor leads to a cure, identification of the responsible tumor is challenging. Recently, several studies showed that systemic sampling ...

Last Updated: 31 Dec 1969

Go To URL
Oncogenic osteomalacia: role of Ga-68 DOTANOC PET/CT scan in identifying the culprit lesion and its management.
 

Author(s): Deepa Singh, Aditi Chopra, Mudalsha Ravina, Srikant Kongara, Eesh Bhatia, Narvesh Kumar, Sushil Gupta, Subhash Yadav, Preeti Dabadghao, Rajnikant Yadav, Veeresh Dube, Utham Kumar, Manish Dixit, Sanjay Gambhir

Journal: Br J Radiol. 2017 Apr;90(1072):20160811.

 

The aim of this study was to evaluate the role of Ga-DOTANOC positron emission tomography (PET)/CT scan in localization of culprit lesion for biopsy and required intervention [surgical excision/radiofrequency ablation (RFA)] in patients with long-standing oncogenic osteomalacia (OOM)/tumour-induced ...

Last Updated: 31 Dec 1969

Go To URL
[Oncogenic osteomalacia. Report of two cases].
 

Author(s): Fernando Jerkovich, Daniel Moncet, Silvia Babini, Jorge A Zoppi, Fabiana Graciolli, Beatriz Oliveri

Journal: Medicina (B Aires). 2015 ;75(1):37-40.

 

Oncogenic osteomalacia is a rare disease. It is caused by a tumor that produces fibroblast growth factor 23, a hormone that decreases the tubular phosphate reabsorption and impairs renal hydroxylation of vitamin D. This leads to hyperphosphaturia with hypophosphatemia and low calcitriol ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Oncogenic osteomalacia" returned 4 free, full-text review articles on human participants. First 3 results:

[Oncogenic osteomalacia and its symptoms: hypophosphatemia, bone pain and pathological fractures].
 

Author(s): Sonia Kaniuka-Jakubowska, Wojciech Biernat, Krzysztof Sworczak

Journal:

 

Oncogenic osteomalacia (OOM) is a rare paraneoplastic syndrome induced by tumor produced phosphaturic factors, i.e. phosphatonins. The disorder is characterized by renal tubular phosphate loss, secondary to this process hypophosphatemia and defective production of active form of vitamin ...

Last Updated: 31 Dec 1969

Go To URL
Dual paraneoplastic syndromes: small cell lung carcinoma-related oncogenic osteomalacia, and syndrome of inappropriate antidiuretic hormone secretion: report of a case and review of the literature.
 

Author(s): Ekamol Tantisattamo, Roland C K Ng

Journal: Hawaii Med J. 2011 Jul;70(7):139-43.

 

Acquired isolated renal phosphate wasting associated with a tumor, known as oncogenic osteomalacia or tumor-induced osteomalacia, is a rare paraneoplastic syndrome caused by overproduction of fibroblast growth factor 23. Oncogenic osteomalacia is usually associated with benign mesenchymal ...

Last Updated: 31 Dec 1969

Go To URL
Oncogenic osteomalacia associated with phosphaturic mesenchymal tumour, mixed connective tissue type of the knee.
 

Author(s): Anna Szumera-Ciećkiewicz, Konrad Ptaszyński, Andrzej Pawełas, Piotr Rutkowski

Journal: Pol J Pathol. 2009 ;60(4):193-8.

 

One of the most unusual and uncommon types of osteomalacia is the oncogenic osteomalacia that is predominantly caused by a soft tissue or bone tumour, mostly by a phosphaturic mesenchymal tumour, mixed connective tissue type (PMTMCT). We report a case of a 27-year-old male presented ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia
 

Status: Recruiting

Condition Summary: Hypophosphatemia

 

Last Updated: 4 Jul 2016

Go to URL